SAB Biotherapeutics's total assets for Q4 2024 were $44.20M, a decrease of -17.85% from the previous quarter. SABS total liabilities were $18.23M for the fiscal quarter, a 7.88% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.